微小RNA在结直肠癌治疗中的研究进展

doi:10.3760/cma.j.issn.1673422X.2015.05.019

摘要/Abstract

摘要： 结直肠癌以微小RNA（miRNA）为例的分子靶向治疗方法已经逐渐进入人们的视野。miRNA通过在肿瘤细胞或其所处微环境中异常表达，影响着结直肠癌的生物学进展。miRNA在特异组织中的高或低表达，可以通过影响癌基因、抑癌基因的表达，或影响肿瘤微环境、肿瘤转移性、肿瘤耐药性等方面达到治疗结直肠癌的效果。现今许多miRNA已经进入动物实验阶段。

关键词: 微RNAs, /结直肠肿瘤/靶向治疗

Abstract: he molecular targeted therapy method using microRNAs (miRNAs) is gradually stepping into people's vision. miRNAs affect colorectal cancer progress via abnormal expression in tumor cells or microenvironment. The high or low expressions of miRNAs in specific tissues probably have an impact on the expressions of oncogenes, tumor suppressor genes or other aspects including the surrounding environments, the metastases and the drug tolerance of tumors, thus contributing to curing the colorectal cancer. Nowadays, miRNA has entered the stage of animal experiments.

林小晶, 许晶晶, 陈燕. 微小RNA在结直肠癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2015, 42(5): 388-391.

LIN Xiao-Jing, XU Jing-Jing, CHEN Yan. Research progress of microRNAs in colorectal cancer therapy[J]. Journal of International Oncology, 2015, 42(5): 388-391.

参考文献

［1］ Wu J, Wu G, Lv L, et al. MicroRNA34a inhibits migration and invasion of colon cancer cells via targeting to Fra1［J］. Carcinogenesis, 2012, 33(3)： 519528. ［2］ Akao Y, Noguchi S, Iio A, et al. Dysregulation of microRNA34a expression causes drugresistance to 5FU in human colon cancer DLD1 cells［J］. Cancer Lett, 2011, 300(2)： 197204. ［3］ Lin PL, Wu DW, Huang CC, et al. MicroRNA21 promotes tumour malignancy via increased nuclear translocation of betacatenin and predicts poor outcome in APCmutated but not in APCwildtype colorectal cancer［J］. Carcinogenesis, 2014, 35(10)： 21752182. ［4］ Peacock O, Lee AC, Cameron F, et al. Inflammation and MiR21 pathways functionally interact to downregulate PDCD4 in colorectal cancer［J］. PLoS One, 2014, 9(10)： e110267. ［5］ Du M, Liu S, Gu D, et al. Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients［J］. Carcinogenesis, 2014, 35(12)： 27232730. ［6］ Oue N, Anami K, Schetter AJ, et al. High miR21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer［J］. Int J Cancer, 2014, 134(8)： 19261934. ［7］ Roy S, Yu Y, Padhye SB, et al. Difluorinatedcurcumin (CDF) restores PTEN expression in colon cancer cells by downregulating miR21［J］. PLoS One, 2013, 8(7)： e68543. ［8］ Hanahan D, Weinberg RA. Hallmarks of cancer： the next generation［J］. Cell, 2011, 144(5)： 646674. ［9］ Kent OA, Chivukula RR, Mullendore M, et al. Repression of the miR143/145 cluster by oncogenic Ras initiates a tumorpromoting feedforward pathway［J］. Genes Dev, 2010, 24(24)： 27542759. ［10］ Chivukula RR, Shi G, Acharya A, et al. An essential mesenchymal function for miR143/145 in intestinal epithelial regeneration［J］. Cell, 2014, 157(5)： 11041116. ［11］ Iliopoulos D. MicroRNA circuits regulate the cancerinflammation link［J］. Sci Signal, 2014, 7(318)： pe8. ［12］ Ma F, Xu S, Liu X, et al. The microRNA miR29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon［gamma］［J］. Nat Immunol, 2011, 12(9)： 861869. ［13］ Borralho PM, Simes AES, Gomes SE, et al. miR143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation［J］. PLoS One, 2011, 6(8)： e23787. ［14］ Yamakuchi M, Lotterman CD, Bao C, et al. P53induced microRNA107 inhibits HIF1 and tumor angiogenesis［J］. Proc Natl Acad Sci USA, 2010, 107(14)： 63346339. ［15］ Ma Y, BaoHan W, Lv X, et al. MicroRNA34a mediates the autocrine signaling of PAR2activating proteinase and its role in colonic cancer cell proliferation［J］. PLoS One, 2013, 8(8)： e72383. ［16］ Yin Y, Yan ZP, Lu NN, et al. Downregulation of miR145 associated with cancer progression and VEGF transcriptional activation by targeting NRAS and IRS1［J］. Biochim Biophys Acta, 2013, 1829(2)： 239247. ［17］ Shen WW, Zeng Z, Zhu WX, et al. MiR1423p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells［J］. J Mol Med, 2013, 91(8)： 9891000. ［18］ KoppersLalic D, Hogenboom MM, Middeldorp JM, et al. Virusmodified exosomes for targeted RNA delivery; a new approach in nanomedicine［J］. Adv Drug Deliv Rev, 2013, 65(3)： 348356. ［19］ Bryniarski K, Ptak W, Jayakumar A, et al. Antigenspecific, antibodycoated, exosomelike nanovesicles deliver suppressor Tcell microRNA150 to effector T cells to inhibit contact sensitivity［J］. J Allergy Clin Immunol, 2013, 132(1)： 170181. ［20］ Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins［J］. Nat Cell Biol, 2011, 13(4)： 423433. ［21］ Liu X, Suo R, Xiong SL, et al. HDL drug carriers for targeted therapy［J］. Clin Chimica Acta, 2013, 415： 94100.

[1]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[2]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[3]	周仁邦, 张仲传, 许志远, 朱勋兵. miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[4]	金嘉会, 陈存海, 马学真. 放射相关miRNA在乳腺癌放疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(12): 735-738.
[5]	井文君, 赵文文, 冯青青, 赵文飞, 赵丽丽, 张雪, 魏红梅. miR-34家族用于胃癌治疗的分子基础及临床前景[J]. 国际肿瘤学杂志, 2022, 49(11): 681-686.
[6]	罗丽云, 赖灿辉, 梁仁佩, 杨爱武, 林志敏. 晚期胃癌中miR-524-5p与SOX9表达的相关性及其对化疗疗效和预后的影响[J]. 国际肿瘤学杂志, 2022, 49(1): 45-50.
[7]	刘佩, 蒲嘉泽, 黄雯, 汪斐. 吉非替尼敏感与耐药NSCLC患者miR-200c、miR-19a、miR-155表达差异及其对患者预后的影响[J]. 国际肿瘤学杂志, 2021, 48(7): 409-414.
[8]	王阳, 刘芊, 龙辉, 吴清明. 结直肠癌标志物粪便检测的研究现状[J]. 国际肿瘤学杂志, 2021, 48(7): 441-444.
[9]	程一鸣, 李刚, 王振明, 吕倩文, 李世荣. 血清miR-196a-5p、miR-105-5p在良恶性肺结节鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(5): 282-286.
[10]	邓波儿, 孔为民. 子宫内膜癌的表观遗传学研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 184-188.
[11]	李炳亮, 杨娅, 黄英丽, 司文, 李兴伟, 张元民, 卞继超, 陈语. miR-20a-5p靶向KDM6B对骨肉瘤细胞增殖、迁移和侵袭能力的影响[J]. 国际肿瘤学杂志, 2021, 48(2): 65-73.
[12]	何苗, 范奎, 曹芳. 表观遗传与肺癌耐药[J]. 国际肿瘤学杂志, 2021, 48(10): 622-626.
[13]	周佳敏, 叶莉莎, 王国华. 微小RNA调控肿瘤相关巨噬细胞极化在重塑乳腺癌免疫微环境中的作用[J]. 国际肿瘤学杂志, 2020, 47(7): 428-430.
[14]	杨立芬, 宋伟, 许大伟, 武军, 高然. miR-103a-3p/CHI3L1在卵巢癌细胞增殖和血管拟生中的作用机制[J]. 国际肿瘤学杂志, 2020, 47(6): 333-339.
[15]	袁霜, 孙笑, 王丽华. 环状RNA与肿瘤耐药的关系[J]. 国际肿瘤学杂志, 2020, 47(4): 223-226.